# Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

> **NCT06902246** · PHASE2 · RECRUITING · sponsor: **University of Miami** · enrollment: 30 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Regorafenib
- **RADIATION:** TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization

## Key facts

- **NCT ID:** NCT06902246
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2031-08-01
- **Final completion:** 2031-08-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06902246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06902246, "Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06902246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*